Caffeine Consumption Contributes to Skin Intrinsic Fluorescence in Type 1 Diabetes

Diabetes Technology and Therapeutics

Volumn 17, Issue 10, 2015, Pages 726-734

  Eny, Karen M ^a   Orchard, Trevor J ^b   Miller, Rachel Grace ^b   Maynard, John ^c   Grant, Denis M ^d   Costacou, Tina ^b   Cleary, Patricia A ^e   Braffett, Barbara H ^e   Paterson, Andrew D ^a,d  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c VeraLight Inc ^*  (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; CAFFEINE; ADVANCED GLYCATION END PRODUCT; COFFEE; NAT2 PROTEIN, HUMAN;

ADOLESCENT; ADULT; ARTICLE; CALORIC INTAKE; COFFEE; DIABETES CONTROL; DIETARY INTAKE; FEMALE; FOLLOW UP; FOOD FREQUENCY QUESTIONNAIRE; GENOTYPE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIGHT EMITTING DIODE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SKIN EXAMINATION; SKIN INTRINSIC FLUORESCENCE; CONTROLLED STUDY; DRUG EFFECTS; FLUORESCENCE; GENETICS; METABOLISM; RANDOMIZED CONTROLLED TRIAL; SKIN; YOUNG ADULT;

ADOLESCENT; ADULT; ARYLAMINE N-ACETYLTRANSFERASE; CAFFEINE; COFFEE; DIABETES MELLITUS, TYPE 1; FEMALE; FLUORESCENCE; GENOTYPE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALE; SKIN; YOUNG ADULT;

EID: 84941360603     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2015.0017     Document Type: Article

References (43)

1. Hull E, Ediger M, Unione A, et al.: Noninvasive, optical detection of diabetes: model studies with porcine skin. Opt Express 2004;12:4496-4510.
2. Meerwaldt R, Graaff R, Oomen PH, et al.: Simple noninvasive assessment of advanced glycation endproduct accumulation. Diabetologia 2004;47:1324-1330.
3. Lutgers HL, Graaff R, de Vries R, et al.: Carotid artery intima media thickness associates with skin autofluoresence in non-diabetic subjects without clinically manifest cardiovascular disease. Eur J Clin Invest 2010; 40:812-817.
4. Orchard TJ, Lyons TJ, Cleary PA, et al.: The association of skin-intrinsic fluorescence with type 1 diabetes complications in the DCCT/EDIC Study. Diabetes Care 2013;36: 3146-3153.
5. Conway B, Edmundowicz D, Matter N, et al.: Skin fluorescence correlates strongly with coronary artery calcification severity in type 1 diabetes. Diabetes Technol Ther 2010;12:339-345.
6. Meerwaldt R, Lutgers HL, Links TP, et al.: Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 2007;30:107-112.
7. Meerwaldt R, Hartog JW, Graaff R, et al.: Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 2005;16:3687-3693.
8. Cleary PA, Braffett BH, Orchard T, et al.: Clinical and technical factors associated with skin intrinsic fluorescence in subjects with type 1 diabetes from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Technol Ther 2013;15:466-474.
9. Garcia-Closas M, Hein DW, Silverman D, et al.: A single nucleotide polymorphism tags variation in the arylamine Nacetyltransferase 2 phenotype in populations of European background. Pharmacogenet Genomics 2011;21:231-236.
10. Eny KM, Lutgers HL, Maynard J, et al.: GWAS identifies a N-acetyltransferase 2 (NAT2) acetylator status tag single nucleotide polymorphism to be a major locus for skin fluorescence. Diabetologia 2014;57:1623-1634.
11. Hein DW, Doll MA, Fretland AJ, et al.: Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 2000;9:29-42.
12. Grant DM, Tang BK, Kalow W: A simple test for acetylator phenotype using caffeine. Br J Clin Pharmacol 1984;17:459-464.
13. Suhre K, Shin SY, Petersen AK, et al.: Human metabolic individuality in biomedical and pharmaceutical research. Nature 2011;477:54-60.
14. Karim MM, Jeon CW, Lee HS, et al.: Simultaneous determination of acetylsalicylic acid and caffeine in pharmaceutical formulation by first derivative synchronous fluorimetric method. J Fluoresc 2006;16:713-721.
15. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
16. Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group: Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 1999;22:99-111.
17. Felipe DL, Hempe JM, Liu S, et al.: Skin intrinsic fluorescence is associated with hemoglobin A1c and hemoglobin glycation index but not mean blood glucose in children with type 1 diabetes. Diabetes Care 2011;34:1816-1820.
18. Richards-Kortum R, Sevick-Muraca E: Quantitative optical spectroscopy for tissue diagnosis. Annu Rev Phys Chem 1996;47:555-606.
19. Schmidt LE, Cox MS, Buzzard IM, et al.: Reproducibility of a comprehensive diet history in the Diabetes Control and Complications Trial. The DCCT Research Group. J Am Diet Assoc 1994;94:1392-1397.
20. Willett WC, Sampson L, Stampfer MJ, et al.: Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol 1985;122:51-65.
21. Salvini S, Hunter DJ, Sampson L, et al.: Food-based validation of a dietary questionnaire: the effects of week-toweek variation in food consumption. Int J Epidemiol 1989;18:858-867.
22. Orchard TJ, Dorman JS, Maser RE, et al.: Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes 1990;39:1116-1124.
23. Jochemsen BM, Mulder DJ, van Doormaal JJ, et al.: Relation between food and drinking habits, and skin autofluorescence and intima media thickness in subjects at high cardiovascular risk. J Food Nutr Res 2009;48:51-58.
24. Varani J, Dame MK, Rittie L, et al.: Decreased collagen production in chronologically aged skin: roles of agedependent alteration in fibroblast function and defective mechanical stimulation. Am J Pathol 2006;168:1861-1868.
25. Fredholm BB, Battig K, Holmen J, et al.: Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 1999;51:83-133.
26. Freedman ND, Park Y, Abnet CC, et al.: Association of coffee drinking with total and cause-specific mortality. N Engl J Med 2012;366:1891-1904.
27. Mitchell DC, Knight CA, Hockenberry J, et al.: Beverage caffeine intakes in the U.S. Food Chem Toxicol 2014; 63:136-142.
28. Lane JD, Feinglos MN, Surwit RS: Caffeine increases ambulatory glucose and postprandial responses in coffee drinkers with type 2 diabetes. Diabetes Care 2008;31:221-222.
29. Amin N, Byrne E, Johnson J, et al.: Genome-wide association analysis of coffee drinking suggests association with CYP1A1/CYP1A2 and NRCAM. Mol Psychiatry 2012;17: 1116-1129.
30. Cornelis MC, Monda KL, Yu K, et al.: Genome-wide metaanalysis identifies regions on 7p21 (AHR) and 15q24 (CYP1A2) as determinants of habitual caffeine consumption. PLoS Genet 2011;7:e1002033.
31. Cornelis MC, Byrne EM, Esko T, et al.: Genome-wide meta-analysis identifies six novel loci associated with habitual coffee consumption. Mol Psychiatry 2015;20:647-656.
32. Suhre K, Wallaschofski H, Raffler J, et al.: A genome-wide association study of metabolic traits in human urine. Nat Genet 2011;43:565-569.
33. Nyeki A, Buclin T, Biollaz J, et al.: NAT2 and CYP1A2 phenotyping with caffeine: head-to-head comparison of AFMU vs. AAMU in the urine metabolite ratios. Br J Clin Pharmacol 2003;55:62-67.
34. Djordjevic N, Carrillo JA, Roh HK, et al.: Comparison of N-acetyltransferase-2 enzyme genotype-phenotype and xanthine oxidase enzyme activity between Swedes and Koreans. J Clin Pharmacol 2012;52:1527-1534.
35. Davey Smith G: Use of genetic markers and gene-diet interactions for interrogating population-level causal influences of diet on health. Genes Nutr 2011;6:27-43.
36. Song F, Qureshi AA, Han J: Increased caffeine intake is associated with reduced risk of basal cell carcinoma of the skin. Cancer Res 2012;72:3282-3289.
37. Conney AH, Lu YP, Lou YR, et al: Mechanisms of caffeine-induced inhibition of UVB carcinogenesis. Front Oncol 2013;3:144.
38. Ahmad I, Ahmed S, Sheraz MA, et al.: Effect of caffeine complexation on the photolysis of riboflavin in aqueous solution: a kinetic study. Chem Pharm Bull (Tokyo) 2009;57:1363-1370.
39. Sikorska E, Gliszczynska-Swiglo A, Insinska-Rak M, et al.: Simultaneous analysis of riboflavin and aromatic amino acids in beer using fluorescence and multivariate calibration methods. Anal Chim Acta 2008;613:207-217.
40. Ding M, Bhupathiraju SN, Satija A, et al.: Long-term coffee consumption and risk of cardiovascular disease: a systematic review and a dose-response meta-analysis of prospective cohort studies. Circulation 2014;129:643-659.
41. Olson BP, Matter NI, Ediger MN, et al.: Noninvasive skin fluorescence spectroscopy is comparable to hemoglobin A1c and fasting plasma glucose for detection of abnormal glucose tolerance. J Diabetes Sci Technol 2013;7:990-1000.
42. Tunnicliffe JM, Eller LK, Reimer RA, et al.: Chlorogenic acid differentially affects postprandial glucose and glucosedependent insulinotropic polypeptide response in rats. Appl Physiol Nutr Metab 2011;36:650-659.
43. Kim J, Jeong IH, Kim CS, et al.: Chlorogenic acid inhibits the formation of advanced glycation end products and associated protein cross-linking. Arch Pharm Res 2011;34: 495-500.